RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
PURPOSE: This randomized phase II trial is studying PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy.
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
OUTLINE: This is a multicenter study. Patients are stratified according to T-stage (T1-2 vs T3-4) and nodal status (N0 vs N+). Patients are randomized to 1 of 2 treatment arms.
Within 4-10 weeks after completion of neoadjuvant chemoradiotherapy, patients undergo surgery at the discretion of the treating team.
Patients may undergo blood sample collection at baseline and periodically during study for correlative studies. Patients may also complete quality-of-life questionnaires at baseline and periodically during study.
After completion of study therapy, patients are followed up periodically for 5 years.
Adenocarcinoma of the Gastroesophageal Junction Esophageal Cancer adenocarcinoma of the esophagus stage IB esophageal cancer stage IIA esophageal cancer stage IIB esophageal cancer stage IIIA esophageal cancer stage IIIB esophageal cancer stage IIIC esophageal cancer Paclitaxel Oxaliplatin Albumin-Bound Paclitaxel Carboplatin Fluorouracil Levoleucovorin Leucovorin
For people ages 18 years and up
© 2017 The Regents of the University of California